Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients

Glycogen Synthase Kinase 3 Clinical Trial

Official title:

Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients: a Randomized Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02686710
• Other study ID #: GSK-TV-L
• Status: Terminated
• Phase: Phase 4
• Start date: February 2016
• Est. completion date: December 2018

Study information

• Verified date: August 2019
• Source: Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assessment of GSK-3beta contents in leukocytes in on-pump cardiosurgical patients receiving either volatile or intravenous anesthesia

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

elective on-pump CABG

Exclusion Criteria:

re-operation

Related Conditions & MeSH terms

• Glycogen Synthase Kinase 3

Intervention

Drug:
• Sevoflurane

• Propofol

Locations

Country	Name	City	State
Russian Federation	Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gsk-3beta base line content		base line
Primary	Gsk-3beta content after induction		20 minutes after tracheal intubation
Primary	Gsk-3beta content after surgery		immediately after surgery